BioCryst Pharmaceuticals | BCRX - 资产



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.71B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


资产 更改 日
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Chugai Pharma JPY 2.27T 203.49B 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
DBV Technologies USD 233.72M 123.22M 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novavax USD 1.04B 133.35M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03